Page 127 - Haematologica-5

BL (9.9 %), 3 with PBL (11.5%) and 3 with ARL, not fur- ther classified (42.9%), after a median follow up of 5.0, 4.6, 3.5 and 6.0 years, respectively. Isolated central nerv- ous system (CNS) relapses were observed in 3 of 29 patients (DLBCL: n=2; BL: n=1). RFS depicted by Kaplan Meier curves is shown in Figure 3C and D. Five-year RFS (5yRFS) was 88.4% (SE 2.9%) in DLBCL, 88.9% (SE 3.5%) in BL, and 88.6% (SE 6.2%) in PBL. By contrast, 5yRFS was lower in patients with ARL, not further classified [57.1% (SE 18.7%); P=0.057) (Figure 3D).
Among patients who achieved CR with first-line R- CHOP-based protocols, 5yRFS was 87.8% (SE 3.1%) and 84.4% (SE 8.3%) in DLBCL and PBL, respectively, as com- pared to 65.5% (SE 12.6) in BL and 40.0% in ARL, not fur- ther classified (SE 21.9%; P=0.005) (Figure 3E). No signifi- cant differences in 5yRFS between ARL subtypes were observed in patients treated with the GMALL protocol
(P=0.884) (Figure 3F), although the number of patients with subtypes other than BL was very small in this analy- sis. Of note, patients with BL who received the GMALL protocol had a significantly better 5yRFS than those receiving R-CHOP-based protocols [94.2% (SE 2.8%) vs. 65.5% (SE 12.6%); P=0.001].
Risk factors for recurrent disease in ARL
Univariate analysis identified several factors associated with a lower risk for ARL relapse such as a low IPI, stage I or II according to the Ann Arbor Staging System, cART given during chemotherapy, CD4 T-cell counts >200x109/L, pathology other than ARL, not further classi- fied, and chemotherapy according to the GMALL-proto- col (Table 2). These factors were analyzed in a multivari- ate Cox proportional hazards model, with backward step- wise elimination based on a Wald statistic with P≤0.1.
Relapses in AIDS-related lymphomas
Figure 1. Flow chart of patients included in the present analysis. NHL: non- Hodgkin lymphoma; T-NHL: T-cell non-Hodgkin lymphoma; CR: complete remis- sion; BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; PBL: plas- mablastic lymphoma; ARL: AIDS-related lymphoma.
haematologica | 2018; 103(5)
859